Abliva AB
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Neurovive Pharmaceutical AB (to 2020)
0
Ending by 2030
Sep 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 26, 2026The maintenance fee for Cyclosporine emulsion (US 9,040,487) comes due Nov 26, 2026. Unpaid by May 26, 2027, it lapses early.
- 1 fee due Dec 4, 2026The maintenance fee for Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation (US 10,307,389) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Jan 28, 2027The maintenance fee for Compound and methods for its production (US 9,090,657) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 2 fees due Mar 1 to 22, 2027 · next Mar 1
- 1 fee due Sep 1, 2027The maintenance fee for Sanglifehrin derivatives and methods for their production (US 9,271,977) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,040,487 | Cyclosporine emulsion In force · From the USPTO record | In force | From the USPTO record | |
| US 9,139,613 | Macrocyclic compounds and methods for their production In force · From the USPTO record | In force | From the USPTO record | |
| US 9,119,853 | Sanglifehrin based compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,271,977 | Sanglifehrin derivatives and methods for their production In force · From the USPTO record | In force | From the USPTO record | |
| US 9,090,657 | Compound and methods for its production In force · From the USPTO record | In force | From the USPTO record | |
| US 10,307,389 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation In force · From the USPTO record | In force | From the USPTO record | |
| US 11,147,789 | Novel Cell-Permeable Succinate Compounds In force · Medium confidence | In force | Medium confidence | |
| US 12,310,940 | Novel Cell-Permeable Succinate Compounds In force · Medium confidence | In force | Medium confidence | |
| US 11,565,998 | Succinate Prodrug, Compositions Containing the Succinate Prodrug and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,162,824 | Succinate Prodrug, Compositions Containing the Succinate Prodrug and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending